Yes, but for B to be considered to "work", it would only have to show SOME improvement in SOME patients. IMO, none of the current therapeutics ( except possibly the super expensive and rare ) monoclonal antibodies, do NOT work. The bar is very low. If we even come close to what we achieved in the preclinical lab / RBL , the value of BRILACIDIN would be PRICELESS !!!
Exactly...all that matters now is whether or not Brilacidin shows efficacy in upcoming Covid trial.
Thankfully, Leo was finally able to get that IND to the FDA in mid to late November. I never expected it to be that long of a wait. But, we are now within weeks of seeing a trial start if Leo's projected timeline is correct.
News 
Market Data 
Discover 
AI
